The hypercalcemia of sarcoidosis is thought to result from the extrarenal overproduction of an active vitamin D sterol (1, 2). We reported (3, 4) that cultured pulmonary alveolar macrophages (PAM) ~ from patients with sarcoidosis are capable of metabolizing 25-hydroxyvitamin D~ (25-OH-Ds) to la,25-dihydroxyvitamin D~ [1,25-(OH)2-Ds], suggesting that 1,25-(OH)2-D3, the naturally occurring active metabolite of vitamin D3, is a hypercalcemia-causing factor in sarcoidosis. However, the characteristics of this 25-OH-Ds-converting activity of sarcoid PAM in vitro are poorly understood. It does appear that the l ahydroxylation process is specific for cells derived from patients with sarcoidosis: 1,25-(OH)2-D~ is not synthesized by PAM from patients with other types of pulmonary disease (4). In addition, the specific activity of the cellular converting reaction is greatest in PAM derived from patients with diffuse, infiltrative pulmonary disease and clinical evidence of abnormal calcium metabolism (3, 4). The aim of the current report is to describe the kinetics of 1,25-(OH)2-D3 production by these cells in vitro and to delineate factors that may be important regulators of the conversion reaction. Abbreviations used in this paper: FCS, fetal calf serum; HPLC, high performance liquid chromatography; IFN, interferon; 1,24,25-(OH)3-D3, 1,24(R),25-trihydroxyvitamin D3; 1,25-(OH)~-D3, I a,25-dihydroxyvitamin Ds; 1 a-OH-D3, 1 a-hydroxyvitamin D3; 24,25-(OH)2-D~, 24(R), 25-dihydroxyvitamin Ds; 25-OH-Ds, 25-hydroxyvitamin Ds; 25,26-(OH)~-D~, 25,26-dihydroxyvitamin Ds; PAM, pulmonary alveolar macrophage. J. Exp. MED.
from the alveolar lavage fluid of five patients with diffuse pulmonary sarcoidosis (biopsy proven). Clinical laboratory data on patients at the time of lavage are shown in Table I . The cells were plated and maintained in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal calf serum (FCS) (KC Biological, Inc., Lenexa, KA), 10 ug/ml insulin, 4 nM glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin at 37°C in an atmosphere of 95% air/5% CO2. The medium was replaced with fresh medium every 3rd d. After 3 d in culture, >98% of the adherent cell population was esterase positive (6) .
Metabolism Experiments. After 5 d in primary culture, the capacity of confluent PAM monolayers from each patient to metabolize 5 nM [3H]25-OH-D3 to [3H]l,25-(OH)2-D3 was established. Thereafter, metabolism experiments were performed in cultures (0.25-1.0 X 106 cells/well) ranging in age from 7 to 17 d, by previously described techniques (3) . Briefly, cultures were preincubated for 16 h in serum-free medium with or without vitamin D3 sterols (solubilized in 0.2% ethanol), dexamethasone, or IFN. This medium was replaced with BGJB medium (Gibco Laboratories) containing radiolabeled sterol and incubated for 3 h in the incubator: accumulation of generated [3H]l,25-(OH)-D3 was linear over 5 h (Fig. 1) . All subsequent experiments were incubated for 3 h. A known amount (150 ng) of unlabeled sterol was then added to the incubation medium, the medium was collected, the monolayer was harvested by scraping, and the medium and cells were extracted in methanol/methylene chloride. The lipid extracts were chromatographed on Sep-Pak cartridges (7) to obtain the vitamin D metabolite fraction of interest. This fraction was then subjected to a three-step purification procedure on normal-phase high performance liquid chromatography (HPLC) over a 3.9 mm X 30 cm #-Porasil column (DuPont Instruments, Wilmington, DE). The first chromatographic purification was performed in n-hexane/methanol/isopropanol (92:4:4) followed by HPLC in methylene chloride/methanol (98:2) and methylene chloride/isopropanol (94:6). The fractions containing the authentic standard of interest were retained, pooled, and subjected to scintillation counting to determine the yield of metabolite. In an attempt to discern factors that influence 1,25-(OH)2-D~ synthesis by sarcoid macrophages in vivo, we investigated in vitro the effects of preexposure of PAM to 1,25-(OH)2-D3 or to glucocorticoid, dexamethasone, or human IFN, known stimulators of macrophage activity. (8) . The only pathologic human condition in which there is good evidence for the extrarenal synthesis of 1,25-(OH)2-D is sarcoidosis (9) . Previous data from our laboratory (3) suggest that the macrophage, a ubiquitous constituent of the noncaseating granulomata of sarcoidosis, is the synthetic source of 1,25-(OH)2-D in the disease. In the current report, kinetic analysis of the 25-OH-Da-lcthydroxylation reaction in cultured PAM from patients with sarcoidosis yielded an apparent Km for 25-OH-Da of 52-210 nM. This value is in the range previously reported for the 25-OH-D3-24-hydroxylase in cultured mouse kidney cells (10) , dispersed rat renal epithelial cells (11) , mouse kidney homogenates (12) , and reconstituted mammalian enzyme (13) . If the proposed affinities of the renal enzyme and the PAM hydroxylating mechanism in vitro are applicable in vivo, then one might predict that the sarcoid macrophage competes with the renal 1ot-hydroxylase for its preferred substrate, 25-OH-D3.
Although the PAM l a-hydroxylation reaction and the renal l a-hydroxylase are similar in their affinity and specificity for 25-hydroxylated substrates, there appear to be some important differences between the two. First, even in the presence of high concentrations of substrate 25-OH-Ds or after preincubation with high concentrations of 1,25-(OH)2-Ds, a potent inducer of the renal 25-OH-D3 24-hydroxylase (14) , the PAM 1 a-hydroxylation process was not accompanied by detectable 24-hydroxylating activity. An accompanying 24-hydroxylase is a characteristic of all the other renal lc~-hydroxylation systems previously described (10-13, 15, 16) . Therefore, unlike the situation in the renal epithelial cell, the sarcoid macrophage does not have a 24-hydroxylase competing for substrate. Furthermore, 1,25-(OH)2-D~ synthesized in the sarcoid PAM is not likely to be metabolized to 1,24,25-(OH)3-Ds, a metabolite that is biologically less potent than 1,25-(OH)2-D3 (17, 18) . A second discrepancy is the apparent lack of metabolic control in the 1 a-hydroxylation of 25-OH-D in hypercalcemic patients with sarcoidosis. Patients 1 and 5 reported here (Table I) (OH)2-Ds induction of its own metabolism, may not be fully operative in the PAM l a-hydroxylation reaction. The lack of accompanying 24-hydroxylating activity and significant product inhibition of the PAM 25-OH-Ds-la-hydroxylation reaction, coupled with the relatively high affinity of the macrophage conversion reaction for 25-OH-D~, suggests that the sarcoid macrophage has the potential to rival the naturally occurring renal enzyme in its efficiency of 1,25-(OH)2-D~ synthesis. These dissimilar characteristics of the PAM and renal hydroxylating mechanisms suggest that the sarcoid macrophage does not harbor the classic l~-hydroxylase (21) . Moreover, it is also unlikely that 1,25-(OH)2-D~ synthesis in sarcoid PAM occurs via the mitochondrial cytochrome P-450-catalyzed peroxygenase pathway recently reported by Warner (21) . In this NADPH-independent system, both 1,25-(OH)2-D~ and 24,25-(OH)2-D3 are generated from substrate 25-OH-D3. No 24,25-(OH)2-D3 production was identified in our metabolism experiments, even at high concentrations of 25-OH-Ds. It is possible that the PAM la-hydroxylation reaction is linked to the production of reactive oxygen intermediates. The generation of hydrogen peroxide by activated human monocytes is exquisitely sensitive to glucocorticoids (23) and may explain the steroidmediated inhibition of 1,25-(OH)2-D3 synthesis by sarcoid PAM. Interestingly, the suppressive action in vitro correlates with the long-recognized antihypercalcemic action of glucocorticoids in vivo in patients with sarcoidosis (24) .
In light of the suppressive actions of glucocorticoids on the generation of 1,25-(OH)2-D3 by sarcoid PAM, we were curious to know whether IFNs, known stimulators of macrophage action, might enhance sterol synthesis by these cells. Mononuclear inflammatory cells, derived from the alveolar space of patients with sarcoidosis and high intensity alveolitis, are prolific in their synthesis of lymphokines, including interleukin 1, interleukin 2, and IFN-3, (25) . As demonstrated in Figs. 6 and 7, IFN-3~ accelerates the velocity of the conversion reaction in PAM in vitro, increasing the synthetic yield of 1,25-(OH)2-Ds by as much as 200%. Whether IFN-3' is an important modulator of macrophage 1,25-(OH)2-D3 synthesis in vivo, and whether 1,25-(OH)2-D3, recently shown (26) to be a specific and potent inhibitor of human T helper/inducer lymphocyte function, is a biologically active lymphokine in the alveolar space in sarcoidosis, are intriguing but yet unanswered questions.
Summary
We investigated the l a-hydroxylation of vitamin Ds sterols by cultured pulmonary alveolar macrophages (PAM) from patients with sarcoidosis with or without clinically abnormal calcium homeostasis. Like the naturally occurring renal l~-hydroxylase, the PAM lo~-hydroxylation reaction exhibited a high affinity for 25-hydroxyvitamin Ds (25-OH-Ds) and a preference for substrates containing a 25-hydroxyl group in the side chain of the sterol. Unlike the renal enzyme, the PAM l o~-hydroxylating mechanism was not accompanied by 24-hydroxylating activity, even after preincubation with 75 nM 1,25-dihydroxyvitamin D3 [1,25-(OH)2-D3] or exposure to high concentrations of substrate (500 nM 25-OH-D3). The PAM 25-OH-D3-1 a-hydroxylation reaction was stimulated by gamma interferon and inhibited by exposure to the glucocorticoid dexamethasone. The characteristics of the PAM hydroxylation process in vitro appear to reflect the efficiency of the extrarenal production of 1,25-(OH)2-Ds and the therapeutic efficacy of glucocorticoids in patients with sarcoidosis and disordered calcium metabolism.
